Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Accumulated Expenses: 2019-2024

Historic Accumulated Expenses for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $19.4 million.

  • C4 Therapeutics' Accumulated Expenses fell 26.76% to $11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.3 million, marking a year-over-year decrease of 26.76%. This contributed to the annual value of $19.4 million for FY2024, which is 6.14% down from last year.
  • Per C4 Therapeutics' latest filing, its Accumulated Expenses stood at $19.4 million for FY2024, which was down 6.14% from $20.6 million recorded in FY2023.
  • C4 Therapeutics' Accumulated Expenses' 5-year high stood at $20.6 million during FY2023, with a 5-year trough of $9.5 million in FY2020.
  • For the 3-year period, C4 Therapeutics' Accumulated Expenses averaged around $19.9 million, with its median value being $19.8 million (2022).
  • Per our database at Business Quant, C4 Therapeutics' Accumulated Expenses spiked by 45.30% in 2022 and then dropped by 6.14% in 2024.
  • Yearly analysis of 5 years shows C4 Therapeutics' Accumulated Expenses stood at $9.5 million in 2020, then skyrocketed by 42.86% to $13.6 million in 2021, then skyrocketed by 45.30% to $19.8 million in 2022, then climbed by 4.36% to $20.6 million in 2023, then declined by 6.14% to $19.4 million in 2024.